Related Experiment Video
Updated: Aug 16, 2026
16:57
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
[Abnormal movements induced by L-dopa. New therapeutic possibilities]
Schweizerische Medizinische Wochenschrift
|January 25, 1975
Summary
A new drug, EP 19-088, shows promise in treating Parkinson's disease patients experiencing involuntary movements. This novel indenopyridine derivative offered symptom relief in a majority of participants, with some experiencing complete cessation of symptoms.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease treatment with L-Dopa often leads to involuntary movements.
- Current management strategies for these dyskinesias include adjusting decarboxylase inhibitor (DCI) dosage or using 3-oxy-methyl-dopa.
Purpose of the Study:
- To evaluate the efficacy and safety of EP 19-088, a novel tricyclic indenopyridine derivative, in Parkinson's disease patients with treatment-resistant involuntary movements.
Main Methods:
- A clinical trial was conducted involving 42 Parkinson's disease patients.
- Patients received the experimental treatment EP 19-088.
- Outcomes assessed included symptom cessation, improvement, lack of effect, and adverse events.
Main Results:
- Complete cessation of symptoms occurred in 12 patients.
- Marked improvement was observed in 9 patients, and slight but definite improvement in 10 others.
- Treatment was discontinued in 2 patients due to confusion; 9 patients showed no effect. No side effects were reported in 24 patients.
Conclusions:
- EP 19-088 demonstrates potential as a therapeutic option for managing involuntary movements in Parkinson's disease.
- The drug was generally well-tolerated, though some adverse effects like confusion and increased fatigability were noted.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:12Alterations in Muscle Tone ll
Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...